1 Min Read
April 18 (Reuters) - Applied Genetic Technologies Corp :
* AGTC DOSES FIRST PATIENT IN PHASE 1/2 CLINICAL STUDY OF GENE THERAPY FOR TREATMENT OF X-LINKED RETINITIS PIGMENTOSA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.